title: Neurotensin receptor 1 overexpression in inflammatory bowel diseases and colitis-associated neoplasia.
abstract: OBJECTIVE
  To explore the association of neurotensin receptor 1 (NTSR1) with inflammatory bowel diseases (IBD) and colitis-associated neoplasia.
  
  
  METHODS
  NTSR1 was detected by immunohistochemistry in clinical samples of colonic mucosa with IBD colitis, colitis-associated raised low-grade dysplasia (LGD) including dysplasia-associated lesions or masses (DALMs, n = 18) and adenoma-like dysplastic polyps (ALDPs, n = 4), colitis-associated high-grade dysplasia (HGD, n = 11) and colitis-associated colorectal carcinoma (CACRC, n = 13), sporadic colorectal adenomatous polyp (SAP, n = 17), and sporadic colorectal carcinoma (SCRC, n = 12). The immunoreactivity of NTSR1 was semiquantitated (as negative, 1+, 2+, and 3+) and compared among different conditions.
  
  
  RESULTS
  NTSR1 was not detected in normal mucosa but was expressed similarly in both active and inactive colitis. LGD showed a significantly stronger expression as compared with non-dysplastic colitic mucosa, with significantly more cases showing > 2+ intensity (68.75% in LGD vs 32.26% in nondysplastic mucosa, P = 0.001). However, no significant difference existed between DALMs and ALDPs. CACRC and HGD showed a further stronger expression, with significantly more cases showing 3+ intensity than that in LGD (61.54% vs 12.50% for CACRC vs LGD, P = 0.022; 58.33% vs 12.50% for CACRC/HGD vs LGD, P = 0.015). No significant difference existed between colitis-associated and non-colitic sporadic neoplasia.
  
  
  CONCLUSIONS
  NTSR1 in colonic epithelial cells is overexpressed in IBD, in a stepwise fashion with sequential progress from inflammation to dysplasia and carcinoma.
authors.affiliation: Calgary Laboratory Services and Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta T2N 2T9, Canada. xsean.gui@cls.ab.ca
authors.forename: Xianyong
authors.initials: X
authors.lastname: Gui
authors.forename: Shuhong
authors.initials: S
authors.lastname: Liu
authors.forename: Yuchu
authors.initials: Y
authors.lastname: Yan
authors.forename: Zuhua
authors.initials: Z
authors.lastname: Gao
mesh_terms: D000236:Adenoma / Q000737:chemistry* / Q000209:etiology / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002277:Carcinoma / Q000737:chemistry* / Q000209:etiology / Q000473:pathology; D003093:Colitis, Ulcerative / Q000150:complications / Q000378:metabolism* / Q000473:pathology; D003106:Colon / Q000737:chemistry* / Q000473:pathology; D003111:Colonic Polyps / Q000737:chemistry* / Q000209:etiology / Q000473:pathology; D015179:Colorectal Neoplasms / Q000737:chemistry* / Q000209:etiology / Q000473:pathology; D003424:Crohn Disease / Q000150:complications / Q000378:metabolism* / Q000473:pathology; D018450:Disease Progression; D005260:Female; D006801:Humans; D007413:Intestinal Mucosa / Q000737:chemistry* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D018028:Receptors, Neurotensin / Q000032:analysis*; D012189:Retrospective Studies; D015854:Up-Regulation
chemical_list: D018028:Receptors, Neurotensin; C114036:neurotensin type 1 receptor
keywords: Colitis-associated neoplasia; Colorectal carcinoma; Dysplasia; Dysplasia-associated lesion or mass; Inflammatory bowel diseases; Neurotensin; Neurotensin receptor; Sporadic adenoma
references.citation: Gastroenterology. 2004 Feb;126(2):451-9
references.pmid: 14762782
references.citation: Peptides. 2007 Oct;28(10):2030-5
references.pmid: 17870207
references.citation: Ann Surg. 1993 May;217(5):439-45; discussion 446
references.pmid: 8387763
references.citation: Am J Physiol Gastrointest Liver Physiol. 2004 Jul;287(1):G7-17
references.pmid: 15194558
references.citation: J Clin Invest. 1999 Mar;103(6):843-9
references.pmid: 10079105
references.citation: Nature. 2012 Oct 25;490(7421):508-13
references.pmid: 23051748
references.citation: Regul Pept. 2006 Jan 15;133(1-3):105-14
references.pmid: 16330112
references.citation: FEBS Lett. 2002 Jul 17;523(1-3):224-8
references.pmid: 12123836
references.citation: Int J Cancer. 2012 Apr 15;130(8):1798-805
references.pmid: 21630261
references.citation: Carcinogenesis. 2006 Apr;27(4):708-16
references.pmid: 16299383
references.citation: Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10613-8
references.pmid: 18650383
references.citation: J Biol Chem. 2012 Apr 27;287(18):15066-75
references.pmid: 22416137
references.citation: Cancer Res. 1992 May 1;52(9 Suppl):2737s-2742s
references.pmid: 1314136
references.citation: J Biol Chem. 2004 Oct 15;279(42):43547-54
references.pmid: 15247267
references.citation: Peptides. 2008 Sep;29(9):1609-15
references.pmid: 18541341
references.citation: World J Gastroenterol. 2008 Feb 28;14(8):1222-30
references.pmid: 18300348
references.citation: Neurogastroenterol Motil. 2009 Apr;21(4):439-50
references.pmid: 19019013
references.citation: Am J Physiol Gastrointest Liver Physiol. 2005 Apr;288(4):G621-9
references.pmid: 15764810
references.citation: Prostate. 1997 May 15;31(3):183-92
references.pmid: 9167771
references.citation: Peptides. 2006 Oct;27(10):2424-33
references.pmid: 16904238
references.citation: N Engl J Med. 1990 Nov 1;323(18):1228-33
references.pmid: 2215606
references.citation: Am J Physiol Cell Physiol. 2003 Jun;284(6):C1397-404
references.pmid: 12584113
references.citation: Regul Pept. 1992 Sep 3;41(1):27-37
references.pmid: 1333624
references.citation: Gut. 2009 Jan;58(1):34-40
references.pmid: 18824554
references.citation: Am J Physiol. 1994 Feb;266(2 Pt 1):G167-78
references.pmid: 8141289
references.citation: Proc Natl Acad Sci U S A. 2009 May 26;106(21):8766-71
references.pmid: 19443690
references.citation: Mol Pharmacol. 2005 Jun;67(6):2025-31
references.pmid: 15755906
references.citation: Clin Cancer Res. 2006 Sep 15;12(18):5346-55
references.pmid: 17000667
references.citation: Cytokine Growth Factor Rev. 2001 Dec;12(4):375-91
references.pmid: 11544106
references.citation: Gastroenterology. 2011 Nov;141(5):1749-61.e1
references.pmid: 21806946